Anal squamous cell carcinoma+4
Not recruitingStudy of pembrolizumab and vorinostat combination therapy in patients with recurrent or metastatic squamous cell carcinoma of head and neck, cervix, anus, and genital areas
Study of pembrolizumab and vorinostat combination therapy in patients with recurrent or metastatic squamous cell carcinoma of head and neck, cervix, anus, and genital areas
- Disease:Anal squamous cell carcinomaSquamous cell carcinoma of head and neck+3
- Substances:PembrolizumabVorinostat
France- Participants:18–64 years · 65+ years
- Substances:Pembrolizumab
- Sponsor:Unicancer











